Insulin Glargine/Lixisenatide

Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Reference #: 25-HFD-45-09-02 Product: Drugs Recipient: Recipient Name Ralph A. DeFronzo, M.D. Recipient Title Department of Medicine, Diabetes Division Ralph A. DeFronzo, M.D./University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive Mail Code 7886 San Antonio , TX 78229-3901 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER FDA Ref No.: 25-HFD-45-09-02 Dear Dr. DeFronzo: This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between December 3 and December 6, 2024. Investigator Ruth E. Medcalf, representing FDA, reviewed your conduct of the following clinical investigations: Protocol (b)(4) , “ (b)(4) ,” of the investigational drugs (b)(4) , performed for (b)(4) . 1 Protocol (b)(4) , “ (b)(4) ,” of the investigational drug (b)(4) , performed for (b)(4) . This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected. At the conclusion of the inspection, Investigator Medcalf presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your December 30, 2024, written response to the Form FDA 483. From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated December 30, 2024, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312) governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following: 1. You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60]. As a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol (b)(4) required you to ensure that subjects met all eligibility criteria before enrollment in the study. For example, all versions of the protocol that was in effect at the time all seven subjects enrolled, required the following inclusion criteria to be eligible for enrollment in the study: blood pressure ≤ 145 / 65 mmHg estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73m² Furthermore, the eligibility criteria for Protocol (b)(4) required subjects who were treated with glucagon-like peptide-1 (GLP-1) receptor agonists or thiazolidinediones, and with sodium-glucose transport protein 2 (SGLT2) inhibitors, to be excluded from participation in the study. You failed to adhere to these requirements. Specifically: a. Subject (b)(6) ’s screening visit blood pressure was 103 / 72 mmHg, which was outside the protocol-specified range for eligibility. However, this subject was enrolled on July 12, 2023, and received study drug. b. Subject (b)(6) ’s screening visit blood pressure was 163 / 92 mmHg, and the subject’s eGFR was 41 ml/min/1.73m², both of which fell outside the protocol-specified ranges for eligibility. Additionally, this subject’s medication list included FARXIGA® (dapagliflozin), an SGLT2 inhibitor, which was an exclusionary medication for study enrollment. However, this subject was enrolled on July 25, 2023, and received study drug. c. Subject (b)(6) ’s medication list included JARDIANCE® (empagliflozin), an SGLT2 inhibitor, which was an exclusionary medication for study enrollment. However, this subject was enrolled on July 26, 2023, and received study drug. d. Subject (b)(6) ’s screening visit blood pressure was 120 / 78 mmHg, which was outside the protocol-specified range for eligibility. However, this subject was enrolled on August 7, 2023, and received study drug. e. Subject (b)(6) ’s screening visit blood pressure was 132 / 67 mmHg, which was outside the protocol-specified range for eligibility. This subject’s medication list included JARDIANCE® (empagliflozin), an SGLT2 inhibitor, and SOLIQUA®, which is a combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, both of which were exclusionary medications for study enrollment. However, this subject was enrolled on August 9, 2023, and received study drug. f. Subject (b)(6) ’s screening visit blood pressure was 112 / 74 mmHg, which was outside the protocol-specified range for eligibility. Also, this subject’s medication list included JARDIANCE® (empagliflozin), an SGLT2 inhibitor, which was an exclusionary medication for study enrollment. However, this subject was enrolled on June 18, 2024, and received study drug. In your December 30, 2024, written response, you stated that the blood pressure requirement defined in the eligibility criteria was a typographical error, and that you modified the protocol accordingly in the protocol version approved by the IRB in September 2024. In this version of the protocol, you also modified the eligibility criteria to allow for eGFR variability, and to allow for inclusion of subjects taking SLGT2 inhibitors and GLP-1 receptor agonists. You noted that the guidelines for (b)(4) therapy have changed significantly since the protocol was first written, noting the benefit of SLGT2 inhibitors and GLP-1 receptor agonists. Your written response further stated that all staff and physicians involved in ongoing clinical studies have been retrained, and all new staff will be thoroughly trained. You also indicated that, for all ongoing studies, a second person involved in the study has been identified, and this second person will check that the eligibility criteria in the protocol and source documents are internally consistent and do not contain any typos. You stated that this person will also check that participants fulfill inclusion/exclusion criteria, and that you will review and sign the inclusion/exclusion page. While we acknowledge your response that you made the necessary changes to the protocol and obtained IRB approval, your response is inadequate because this approval of the protocol with the above-noted modified inclusion criteria occurred more than a year after all seven subjects were enrolled. Further, your corrective actions are inadequate because your written response does not provide sufficient details about how you, as a clinical investigator, will ensure adequate oversight of the study procedures and will prevent similar violations in the future. We emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, both to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to ensure that subjects met eligibility criteria before their enrollment in the study raises significant concerns about the safety of subjects enrolled in this study and the reliability of data at your site. 2. You failed to promptly report all changes in research activity to the Institutional Review Board (IRB) [21 CFR 312.66]. As a clinical investigator, you are required to promptly report all changes in research activity to the IRB. You failed to adhere to this requirement. Specifically, for Protocol (b)(4) , you did not promptly report to the IRB that the study design of the clinical investigation was modified from a double-blind, placebo-controlled, randomized clinical trial to a two-part clinical trial that included an initial pilot feasibility study of 10 to 12 participants, followed by a double-blind, placebo-controlled, randomized clinical trial. As a result, all seven enrolled subjects received the investigational drug, because the change in study design eliminated the placebo control group; further, this occurred before you received IRB approval for the modification on September 23, 2024. We note that the approval of the protocol with the above-noted modified study design occurred more than one year after all seven subjects were enrolled and treated with the investigational drug. Additionally, we are particularly concerned that all seven enrolled subjects were consented using an informed consent document that detailed the study procedures, risks, benefits, and rights of study participants for the original double-blind, placebo-controlled, randomized clinical trial, not for the clinical trial with the modified study design that included the initial pilot feasibility study. In your December 30, 2024, written response, you acknowledged that the protocol needed to reflect exactly how the subjects are enrolled into the study. You stated that you had addressed this issue with the IRB, including that you have since updated the informed consent form for this study. You also explained that all study participants were verbally informed at the time of consent that they would receive study drug ( (b)(4) ) and not a placebo. You noted that all staff and physicians involved in ongoing clinical studies have been retrained, and that all new staff will be thoroughly trained, which will include their attending IRB training courses. While we acknowledge the corrective actions that your site has taken and plans to take, your response is inadequate because you have not provided sufficient details about your corrective action plan. For example, you did not provide sufficient details about the policies, procedures, and training plan being implemented at your site to prevent similar violations in the future. We emphasize that, as the clinical investigator, you are responsible for promptly reporting to the IRB all changes in research activity. Your failure to promptly report all changes in research activity to the IRB prevented the IRB from making an informed determination regarding the continued protection of the rights, safety, and welfare of human subjects enrolled in your clinical investigation. This failure potentially compromised the ethical conduct of the study and the validity of the informed consent process for all seven enrolled subjects. This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations. This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration. Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to: Brittany L. Garr-Colón, MPH Branch Chief Compliance Enforcement Branch Division of Enforcement and Postmarketing Safety Office of Scientific Investigations Office of Compliance Center for Drug Evaluation and Research U.S. Food and Drug Administration Building 51, Room 5352 10903 New Hampshire Avenue Silver Spring, MD 20993 Sincerely yours, {See appended electronic signature page} David C. Burrow, Pharm.D., J.D. Director Office of Scientific Investigations Office of Compliance Center for Drug Evaluation and Research U.S. Food and Drug Administration -------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. -------------------------------------------------------------------------------------------- /s/ ------------------------------------------------------------ DAVID C BURROW 09/17/2025 06:49:26 AM _____________________________ 1 Protocol (b)(4) was performed under an investigational new drug application, sponsored by (b)(4) , M.D., for the use of investigational drug (b)(4) in this clinical investigation. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.